eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | paroxysmal nocturnal hemoglobinuria |
| Symptom | C0235574|intravascular hemolysis |
| Sentences | 2 |
| PubMedID- 22350448 | The targeted terminal complement inhibitor eculizumab (soliris) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (pnh), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed red cell transfusions. |
| PubMedID- 20145265 | Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through c3 opsonization. |
Page: 1